Clinical spectrum of extreme insulin resistance syndromes treated with rhIGF-1: A single-center experience - Takeaways - MDSpire

Clinical spectrum of extreme insulin resistance syndromes treated with rhIGF-1: A single-center experience

  • By

  • Nicola Improda

  • Harshini Katugampola

  • Manuela Cerbone

  • Pratik Shah

  • Saji Alexander

  • Abigail Atterbury

  • Smail Hadj-Rabia

  • Catherine J Peters

  • Robert K Semple

  • Mehul Tulsidas Dattani

  • January 28, 2026

  • 0 min

Share

  • 1

    Donohue syndrome (DS) and Rabson-Mendenhall syndrome (RMS) are severe insulin resistance conditions caused by mutations in the insulin receptor gene.

  • 2

    Recombinant human insulin-like growth factor-1 (rhIGF-1) treatment shows short-term metabolic benefits but limited long-term efficacy in patients with DS and RMS.

  • 3

    The study reports outcomes for four patients treated with rhIGF-1, expanding knowledge on the clinical features and treatment responses of these syndromes.

  • 4

    Two patients experienced poor response or intolerance to rhIGF-1 and died in infancy, highlighting the treatment's risks.

  • 5

    Current treatment options for DS and RMS remain inadequate, necessitating further research to explore alternative strategies for severe insulin resistance.

Original Source(s)

Clinical spectrum of extreme insulin resistance syndromes treated with rhIGF-1: A single-center experience

  • by Nicola Improda, Harshini Katugampola, Manuela Cerbone, Pratik Shah, Saji Alexander, Abigail Atterbury, Smail Hadj-Rabia, Catherine J Peters, Robert K Semple, Mehul Tulsidas Dattani

  • January 28, 2026

Related Content

AI system shows high accuracy for diabetic retinopathy screening

"AI could help reduce the burden on ophthalmology services by triaging large numbers of patients with diabetes and allowing specialists to focus on those who most urgently need care."

Diabetes Mellitus Coding in Retina

Age-related macular degeneration (AMD) is among the most common retinal diagnoses. Although the clinical features of the disease are well known, ICD-10 coding can be confusing if details such as stage, activity, and laterality are not clearly documented. Incomplete documentation may prompt questions about the medical necessity of diagnostic tests or intravitreal injections. This Q&A addresses common sources of confusion and offers practical guidance to support clear, accurate documentation.

Progress and Obstacles in Understanding Pathological Mechanisms and Developing Intelligent Diagnostic Approaches for Diabetic Optic Neuropathy